home / stock / pypd / pypd news

PYPD News and Press, PolyPid Ltd. From 06/02/22

Stock Information
Company Name: PolyPid Ltd.
Stock Symbol: PYPD
Market: NASDAQ
Website: polypid.com
Menu
PYPD PYPD Quote PYPD Short PYPD News PYPD Articles PYPD Message Board
Get PYPD Alerts

News, Short Squeeze, Breakout and More Instantly...
PYPD - PolyPid to Present at the JMP Securities 2022 Life Sciences Conference

PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life S...
PYPD - PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects

Locally Administered Docetaxel Through Extended-Release Delivery via the Company’s PLEX Technology Offers Potentially Enhanced Adjuvant Chemotherapy Option PETACH TIKVA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPi...

PYPD - PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX??? for Prevention of Surgical Site Infections in Abdominal Surgery

Following Unblinded Interim Efficacy Analysis, Data Safety Monitoring Board Recently Recommended Concluding Study at 950 Patients, the Minimum Number of Patients Targeted Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 ...

PYPD - PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX??? at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days • Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 • Conference Call...
PYPD - PolyPid Ltd. (NASDAQ: PYPD) Featured in Coverage of Investor Summit Group's Q2 Virtual Event

PolyPid (NASDAQ: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, e...

PYPD - PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q1 2022 Results - Earnings Call Transcript

PolyPid Ltd. (PYPD) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Amir Weisberg - Chief Executive Officer Dikla Czaczkes Akselbrad - Executive Vice President and Chief Financial Officer Ori Warshavsky - Chief Ope...

PYPD - PolyPid GAAP EPS of $0.63 beats by $1.29

PolyPid press release (NASDAQ:PYPD): Q1 GAAP EPS of $0.63 beats by $1.29. Cash and cash equivalents of $11.44M For further details see: PolyPid GAAP EPS of $0.63 beats by $1.29

PYPD - PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results

•  Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently •  Recruitment Progressing as Planned with A pproximately 900 Patien...

PYPD - PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022

PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial r...

PYPD - PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine

Presentation evaluates the effect of D-PLEX 100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “...
Previous 10 Next 10